Total Payments
$160,415
2024 Payments
$26,061
Companies
23
Transactions
246
Medicare Patients
64
Medicare Billing
$13,299
Payment Breakdown by Category
Consulting$64,876 (40.4%)
Other$60,462 (37.7%)
Travel$14,911 (9.3%)
Research$12,814 (8.0%)
Food & Beverage$7,062 (4.4%)
Education$288.38 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $64,876 | 21 | 40.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $56,863 | 26 | 35.4% |
| Travel and Lodging | $14,911 | 45 | 9.3% |
| Unspecified | $12,814 | 30 | 8.0% |
| Food and Beverage | $7,062 | 109 | 4.4% |
| Honoraria | $3,600 | 2 | 2.2% |
| Education | $288.38 | 13 | 0.2% |
Payments by Type
General
$147,601
216 transactions
Research
$12,814
30 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $137,912 | 173 | $0 (2024) |
| Spark Therapeutics, Inc. | $5,937 | 7 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,320 | 7 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $2,764 | 4 | $0 (2023) |
| Amicus Therapeutics, Inc. | $2,596 | 3 | $0 (2024) |
| Horizon Therapeutics plc | $2,100 | 1 | $0 (2020) |
| Horizon Pharma plc | $1,784 | 5 | $0 (2018) |
| BioMarin Pharmaceutical Inc. | $1,670 | 17 | $0 (2023) |
| Cycle Pharmaceuticals Inc | $776.00 | 3 | $0 (2020) |
| Chiesi USA, Inc. | $104.33 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $26,061 | 24 | GENZYME CORPORATION ($25,843) |
| 2023 | $27,452 | 30 | GENZYME CORPORATION ($22,134) |
| 2022 | $25,291 | 28 | GENZYME CORPORATION ($25,147) |
| 2021 | $12,395 | 20 | GENZYME CORPORATION ($6,262) |
| 2020 | $19,813 | 27 | GENZYME CORPORATION ($12,723) |
| 2019 | $35,026 | 57 | GENZYME CORPORATION ($34,691) |
| 2018 | $6,405 | 23 | GENZYME CORPORATION ($4,569) |
| 2017 | $7,972 | 37 | GENZYME CORPORATION ($6,543) |
All Payment Transactions
246 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,352.00 | General |
| Category: Genetic Disease | ||||||
| 12/11/2024 | GENZYME CORPORATION | XENPOZYME (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Genetic Disease | ||||||
| 12/05/2024 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,352.00 | General |
| Category: Genetic Disease | ||||||
| 12/05/2024 | GENZYME CORPORATION | XENPOZYME (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Genetic Disease | ||||||
| 12/05/2024 | GENZYME CORPORATION | XENPOZYME (Biological) | Travel and Lodging | Cash or cash equivalent | $49.58 | General |
| Category: Genetic Disease | ||||||
| 12/05/2024 | GENZYME CORPORATION | XENPOZYME (Biological) | Travel and Lodging | Cash or cash equivalent | $13.88 | General |
| Category: Genetic Disease | ||||||
| 11/30/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,356.00 | General |
| 10/10/2024 | GENZYME CORPORATION | NEXVIAZYME (Biological) | Food and Beverage | In-kind items and services | $35.40 | General |
| Category: Genetic Disease | ||||||
| 09/04/2024 | GENZYME CORPORATION | XENPOZYME (Biological), CEREZYME | Food and Beverage | In-kind items and services | $54.30 | General |
| Category: Genetic Disease | ||||||
| 09/03/2024 | Amicus Therapeutics, Inc. | Pombiliti (Drug), Opfolda | Food and Beverage | In-kind items and services | $66.10 | General |
| Category: Pompe Disease | ||||||
| 08/20/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $7,680.00 | General |
| 08/20/2024 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $331.95 | General |
| 08/20/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $300.31 | General |
| 08/20/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $204.27 | General |
| 08/20/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $158.70 | General |
| 06/01/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,608.00 | General |
| 05/15/2024 | GENZYME CORPORATION | CERDELGA (Drug), NEXVIAZYME, XENPOZYME | Food and Beverage | In-kind items and services | $84.59 | General |
| Category: Genetic Disease | ||||||
| 02/29/2024 | Mirum Pharmaceuticals, Inc. | Cholbam (Drug) | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: Hepatology | ||||||
| 02/08/2024 | Amicus Therapeutics, Inc. | Pombiliti (Drug), Opfolda | Food and Beverage | In-kind items and services | $129.52 | General |
| Category: Pompe Disease | ||||||
| 02/07/2024 | GENZYME CORPORATION | NEXVIAZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Genetic Disease | ||||||
| 02/07/2024 | GENZYME CORPORATION | NEXVIAZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Genetic Disease | ||||||
| 02/07/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $134.31 | General |
| 02/07/2024 | GENZYME CORPORATION | NEXVIAZYME (Biological) | Food and Beverage | In-kind items and services | $25.03 | General |
| Category: Genetic Disease | ||||||
| 01/24/2024 | GENZYME CORPORATION | XENPOZYME (Biological) | Food and Beverage | In-kind items and services | $102.65 | General |
| Category: Genetic Disease | ||||||
| 12/05/2023 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,768.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A phase 4, open label, prospective study in patients with Pompe disease to evaluate the efficacy and safety of alglucosidase alfa produced at the 4000L scale | GENZYME CORPORATION | $2,775 | 4 |
| An open-label ascending dose cohort study to assess the safety, pharmacokinetics, and preliminary efficacy of avalglucosidase alfa (neoGAA, GZ402666) in patients with infantile-onset Pompe disease tre | GENZYME CORPORATION | $2,537 | 9 |
| An open-label ascending dose cohort study to assess the safety, pharmacokinetics, and preliminary efficacy of avalglucosidase alfa (neoGAA, GZ402666) in patients with infantile-onset Pompe disease t | GENZYME CORPORATION | $2,003 | 6 |
| An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response | GENZYME CORPORATION | $2,000 | 5 |
| An open-label ascending dose cohort study to assess the safety, pharmacokinetics, and preliminary efficacy of avalglucosidase alfa (neoGAA, GZ402666) in patients with infantile-onset Pompe disease treated with alglucosidase alfa who demonstrate clinical decline or sub-optimal clinical response | GENZYME CORPORATION | $1,500 | 4 |
| A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale | GENZYME CORPORATION | $1,250 | 1 |
| An open-label ascending dose cohort study to assess the safety, pharmacokinetics, and preliminary efficacy of avalglucosidase alfa (neoGAA, GZ402666) in patients with infantile-onset Pompe disease treated with alglucosidase alfa who demonstrate clinical d | GENZYME CORPORATION | $750.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 27 | 29 | $19,800 | $5,236 |
| 2022 | 1 | 12 | 16 | $9,024 | $2,726 |
| 2021 | 1 | 11 | 16 | $8,259 | $2,650 |
| 2020 | 1 | 14 | 22 | $9,042 | $2,687 |
Total Patients
64
Total Services
83
Medicare Billing
$13,299
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $11,340 | $2,760 | 24.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 15 | $8,460 | $2,476 | 29.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 16 | $9,024 | $2,726 | 30.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 11 | 16 | $8,259 | $2,650 | 32.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 14 | 22 | $9,042 | $2,687 | 29.7% |
About Dr. David Kronn, MD
Dr. David Kronn, MD is a Pediatrics healthcare provider based in Valhalla, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1619979697.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Kronn, MD has received a total of $160,415 in payments from pharmaceutical and medical device companies, with $26,061 received in 2024. These payments were reported across 246 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($64,876).
As a Medicare-enrolled provider, Kronn has provided services to 64 Medicare beneficiaries, totaling 83 services with total Medicare billing of $13,299. Data is available for 4 years (2020–2023), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Clinical Genetics (M.D.)
- Location Valhalla, NY
- Active Since 08/10/2005
- Last Updated 05/21/2021
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1619979697
Products in Payments
- LUMIZYME (Drug) $25,938
- XENPOZYME (Biological) $18,987
- NEXVIAZYME (Biological) $16,422
- LUMIZYME (Biological) $13,946
- DISEASE STATE (Drug) $8,842
- NO PRODUCT DISCUSSED (Drug) $6,889
- RAVICTI (Drug) $3,863
- ALDURAZYME (Drug) $2,520
- POMBILITI (Drug) $2,400
- Kuvan (Drug) $1,374
- MYOZYME (Drug) $1,372
- Nityr (Drug) $776.00
- Pombiliti (Drug) $195.62
- Palynziq (Drug) $125.00
- FABRAZYME (Biological) $108.25
- VYVANSE (Drug) $105.77
- LAMZEDE (Drug) $104.33
- GAUCHER-DISEASE (Drug) $99.74
- XLSD (Drug) $99.01
- CERDELGA (Drug) $84.59
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Valhalla
Margot Marrero-Stein, Rn-Pnp, RN-PNP
Pediatrics — Payments: $21,478
Pediatrics $21,478
Mrs. Karen Wolownik, Msn, Cpnp, MSN, CPNP
Pediatrics — Payments: $14,028
Pediatrics $14,028
Dr. Hanan Tawadrous, M.d, M.D
Pediatrics — Payments: $3,995
Pediatrics $3,995
Dr. Sabrina Malik, Md, MD
Pediatrics — Payments: $3,465
Pediatrics $3,465
Dr. Dinabel Peralta-Reich, M.d, M.D
Pediatrics — Payments: $3,430
Pediatrics $3,430
Dr. Akhil Maheshwari, M.d, M.D
Pediatrics — Payments: $3,300
Pediatrics $3,300